Applications of synthetic biology in the treatment and prevention of infectious diseases

doi:10.12211/2096-8280.2020-021

Abstract

Abstract:

Synthetic biology is bringing together engineers and biologists to design and create novel biological blocks, networks and pathways, which are used to construct, rewire and reprogram organisms. Over the past two decades, scientists have designed and built increasingly complex circuits and constructs for applications to a variety of settings, including biomedicine. Multidrug-resistant infections have emerged as a major threat to hospitalized patients due to the prevalent and often inappropriate use of broad-spectrum antibiotics, which are associated with the boost of mortality. The technologies of synthetic biology have contributed to the understanding of mechanism and provided design of novel strategies. In this review, we first describe CRISPR-Cas based technology for diagnostics, such as SHERLOCK and DETECTR, and then discuss engineered phages, bacteria and the strategies of synthetic biology for combating drug resistance and bacterial biofilms. Also, synthetic biology principle of ‘analysis by synthesis’ as well as CRISPR technology have been applied to unravel mechanism of viral infectious disease and to develop therapies. Finally, we summarize the applications of synthetic biology in prevention of infectious diseases, including engineered probiotic bacteria, vaccine development and control of infectious vectors.

Key words: synthetic biology, CRISPR, treatment and prevention of infectious diseases, biofilms

摘要：

合成生物学是一门综合基因组学、分子生物学和工程学等一系列方法和原理而形成的综合性学科。随着合成生物学理论和技术的不断发展，科学家们设计和构建了越来越复杂的基因回路和元件，并开始在各种领域中使用这些系统，其中就包括生物医学领域。因新抗病原体药物研发速度逐渐落后于耐药性病原体出现的速度，感染性疾病的治疗已经成为现代医学重点关注的课题,对此，应用于感染性疾病的合成生物学疗法不断被尝试。本文概述了感染性疾病及其治疗的困难，简述了利用合成生物学对抗感染性疾病的优势和CRISPR技术在感染性疾病诊断中的应用，重点介绍了合成生物学在细菌和病毒感染性疾病治疗中的应用及在感染性疾病预防中的应用，感染性疾病预防具体包括预防性工程菌的构建、疫苗的研发和感染源的改造。通过回顾合成生物学家为研究感染性疾病的治疗及预防做出的努力，期望能获得新的灵感。虽然目前合成生物学疗法还处在试验阶段，但在感染性疾病防治研究中已经取得了不小的进展，可预见合成生物学将在该领域获得突破并做出贡献。

关键词: 合成生物学, CRISPR, 感染性疾病防治, 细菌生物被膜

CLC Number:

Lu PU, Yajia HUANG, Shuai YANG, Fan JIN. Applications of synthetic biology in the treatment and prevention of infectious diseases[J]. Synthetic Biology Journal, 2020, 1(2): 141-157.

蒲璐, 黄亚佳, 杨帅, 金帆. 合成生物学在感染性疾病防治中的应用[J]. 合成生物学, 2020, 1(2): 141-157.

Figures/Tables 1

References 103

1	MARNER W D. Practical application of synthetic biology principles [J]. Biotechnology Journal: Healthcare Nutrition Technology, 2009, 4(10): 1406-1419.
2	LARTIGUE C, VASHEE S, ALGIRE M A, et al. Creating bacterial strains from genomes that have been cloned and engineered in yeast [J]. Science, 2009, 325(5948): 1693-1696.
3	QUAN J, SAAEM I, TANG N, et al. Parallel on-chip gene synthesis and application to optimization of protein expression [J]. Nature Biotechnology, 2011, 29(5): 449.
4	KOSURI S, EROSHENKO N, LEPROUST E M, et al. Scalable gene synthesis by selective amplification of DNA pools from high-fidelity microchips [J]. Nature Biotechnology, 2010, 28(12): 1295.
5	NANDAGOPAL N, ELOWITZ M B. Synthetic biology: integrated gene circuits [J]. Science, 2011, 333(6047): 1244-1248.
6	TIGGES M, FUSSENEGGER M. Recent advances in mammalian synthetic biology-design of synthetic transgene control networks [J]. Current Opinion in Biotechnology, 2009, 20(4): 449-460.
7	WEBER W, FUSSENEGGER M. Synthetic gene networks in mammalian cells [J]. Current Opinion in Biotechnology, 2010, 21(5): 690-696.
8	WIN M N, LIANG J C, SMOLKE C D. Frameworks for programming biological function through RNA parts and devices [J]. Chemistry & Biology, 2009, 16(3): 298-310.
9	BENENSON Y. RNA-based computation in live cells [J]. Current Opinion in Biotechnology, 2009, 20(4): 471-478.
10	CANTON B, LABNO A, ENDY D. Refinement and standardization of synthetic biological parts and devices [J]. Nature Biotechnology, 2008, 26(7): 787-793.
11	HOOSHANGI S, THIBERGE S, WEISS R. Ultrasensitivity and noise propagation in a synthetic transcriptional cascade [J]. PNAS, 2005, 102(10): 3581-3586.
12	KRAMER B P, FISCHER M, FUSSENEGGER M. Semi-synthetic mammalian gene regulatory networks [J]. Metabolic Engineering, 2005, 7(4): 241-250.
13	GARDNER T S, CANTOR C R, COLLINS J J. Construction of a genetic toggle switch in Escherichia coli [J]. Nature, 2000, 403(6767): 339-342.
14	KRAMER B P, VIRETTA A U, DAOUD-EL BABA M, et al. An engineered epigenetic transgene switch in mammalian cells [J]. Nature Biotechnology, 2004, 22(7): 867-870.
15	DANINO T, MONDRAGóN-PALOMINO O, TSIMRING L, et al. A synchronized quorum of genetic clocks [J]. Nature, 2010, 463(7279): 326-330.
16	RUDER W C, LU T, COLLINS J J. Synthetic biology moving into the clinic [J]. Science, 2011, 333(6047): 1248-1252.
17	MAY M. Synthetic biology's clinical applications [J]. Science, 2015, 349(6255): 1564-1566.
18	ANDERSON R M, ANDERSON B, MAY R M. Infectious diseases of humans: dynamics and control [M]. Oxford: Oxford University Press, 1992.
19	KEELING M J, ROHANI P. Modeling infectious diseases in humans and animals [M]. Princeton: Princeton University Press, 2011.
20	KOLLEF M H, SHERMAN G, WARD S, et al. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients [J]. Chest, 1999, 115(2): 462-474.
21	PARDEE K, GREEN A A, TAKAHASHI M K, et al. Rapid, low-cost detection of Zika virus using programmable biomolecular components [J]. Cell, 2016, 165(5): 1255-1266.
22	ABUDAYYEH O O, GOOTENBERG J S, KONERMANN S, et al. C2c2 is a single-component programmable RNA-guided RNA-targeting CRISPR effector [J]. Science, 2016, 353(6299): AAf5573.
23	GOOTENBERG J S, ABUDAYYEH O O, LEE J W, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2 [J]. Science, 2017, 356(6336): 438-442.
24	GOOTENBERG J S, ABUDAYYEH O O, KELLNER M J, et al. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a, and Csm6 [J]. Science, 2018, 360(6387): 439-444.
25	ENGLISH M A, SOENKSEN L R, GAYET R V, et al. Programmable CRISPR-responsive smart materials [J]. Science, 2019, 365(6455): 780-785.
26	FREIJE C A, MYHRVOLD C, BOEHM C K, et al. Programmable inhibition and detection of RNA viruses using Cas13 [J]. Molecular Cell, 2019, 76(5): 826-837, E11.
27	CHEN J S, MA E, HARRINGTON L B, et al. CRISPR-Cas12a target binding unleashes indiscriminate single-stranded DNase activity [J]. Science, 2018, 360(6387): 436-439.
28	LI S Y, CHENG Q X, LIU J K, et al. CRISPR-Cas12a has both cis- and trans-cleavage activities on single-stranded DNA [J]. Cell Research, 2018, 28(4): 491-493.
29	LI S Y, CHENG Q X, WANG J M, et al. CRISPR-Cas12a-assisted nucleic acid detection [J]. Cell Discovery, 2018, 4(1): 20.
30	MALEK A, RAAD I. Catheter- and device-related infections in critically Ill cancer patients [M]. Berlin: Springer, 2020: 1401-1417.
31	HøIBY N, CIOFU O, JOHANSEN H K, et al. The clinical impact of bacterial biofilms [J]. International Journal of Oral Science, 2011, 3(2): 55-65.
32	FLEMMING H C, WINGENDER J. The biofilm matrix [J]. Nature Reviews Microbiology, 2010, 8(9): 623-633.
33	DONLAN R M. Biofilm formation: a clinically relevant microbiological process [J]. Clinical Infectious Diseases, 2001, 33(8): 1387-1392.
34	STEWART P S, COSTERTON J W. Antibiotic resistance of bacteria in biofilms [J]. The Lancet, 2001, 358(9276): 135-138.
35	CHUA S L, LIU Y, YAM J K H, et al. Dispersed cells represent a distinct stage in the transition from bacterial biofilm to planktonic lifestyles [J]. Nature Communications, 2014, 5(1): 4462.
36	LU T K, COLLINS J J. Dispersing biofilms with engineered enzymatic bacteriophage [J]. PNAS, 2007, 104(27): 11197-11202.
37	YEHL K, LEMIRE S, YANG A C, et al. Engineering phage host-range and suppressing bacterial resistance through phage tail fiber mutagenesis [J]. Cell, 2019, 179(2): 459-469, E9.
38	FU W, FORSTER T, MAYER O, et al. Bacteriophage cocktail for the prevention of biofilm formation by Pseudomonas aeruginosa on catheters in an in vitro model system [J]. Antimicrobial Agents and Chemotherapy, 2010, 54(1): 397-404.
39	ALVES D, GAUDION A, BEAN J, et al. Combined use of bacteriophage K and a novel bacteriophage to reduce Staphylococcus aureus biofilm formation [J]. Appl. Environ. Microbiol., 2014, 80(21): 6694-6703.
40	GUTIÉRREZ D, VANDENHEUVEL D, MARTíNEZ B, et al. Two phages, phiIPLA-RODI and phiIPLA-C1C, lyse mono-and dual-species staphylococcal biofilms [J]. Appl. Environ. Microbiol., 2015, 81(10): 3336-3348.
41	LEHMAN S M, DONLAN R M. Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an in vitro urinary catheter model [J]. Antimicrobial Agents and Chemotherapy, 2015, 59(2): 1127-1137.
42	ALVES D R, PEREZ‐ESTEBAN P, KOT W, et al. A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions [J]. Microbial Biotechnology, 2016, 9(1): 61-74.
43	RYAN E M, ALKAWAREEK M Y, DONNELLY R F, et al. Synergistic phage-antibiotic combinations for the control of Escherichiacoli biofilms in vitro [J]. FEMS Immunology & Medical Microbiology, 2012, 65(2): 395-398.
44	RAHMAN M, KIM S, KIM S M, et al. Characterization of induced Staphylococcus aureus bacteriophage SAP-26 and its anti-biofilm activity with rifampicin [J]. Biofouling, 2011, 27(10): 1087-1093.
45	BEDI M S, VERMA V, CHHIBBER S. Amoxicillin and specific bacteriophage can be used together for eradication of biofilm of Klebsiella pneumoniae B5055 [J]. World Journal of Microbiology and Biotechnology, 2009, 25(7): 1145.
46	KOHANSKI M A, DWYER D J, HAYETE B, et al. A common mechanism of cellular death induced by bactericidal antibiotics [J]. Cell, 2007, 130(5): 797-810.
47	LU T K, COLLINS J J. Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy [J]. PNAS, 2009, 106(12): 4629-4634.
48	吴楠楠, 朱同玉. 噬菌体在实体器官移植中的应用 [J]. 器官移植, 2019(4): 410-415.
	WU N N, ZHU T Y. Application of phage in solid organ transplantation [J]. Organ Transplantation, 2019(4): 410-415.
49	RIGLAR D T, SILVER P A. Engineering bacteria for diagnostic and therapeutic applications [J]. Nature Reviews Microbiology, 2018, 16(4): 214-225.
50	SAEIDI N, WONG C K, LO T M, et al. Engineering microbes to sense and eradicate Pseudomonas aeruginosa, a human pathogen [J]. Molecular Systems Biology, 2011, 7(1): 521-531.
51	GRAY K M, PASSADOR L, IGLEWSKI B H, et al. Interchangeability and specificity of components from the quorum-sensing regulatory systems of Vibrio fischeri and Pseudomonas aeruginosa [J]. Journal of Bacteriology, 1994, 176(10): 3076-3080.
52	PU L, YANG S, XIA A, et al. Optogenetics manipulation enables prevention of biofilm formation of engineered Pseudomonas aeruginosa on surfaces [J]. ACS Synthetic Biology, 2018, 7(1): 200-208.
53	OHLENDORF R, VIDAVSKI R R, ELDAR A, et al. From dusk till dawn: one-plasmid systems for light-regulated gene expression [J]. Journal of Molecular Biology, 2012, 416(4): 534-542.
54	COTTER P A, STIBITZ S. c-di-GMP-mediated regulation of virulence and biofilm formation [J]. Current Opinion in Microbiology, 2007, 10(1): 17-23.
55	CHUA K J, KWOK W C, AGGARWAL N, et al. Designer probiotics for the prevention and treatment of human diseases [J]. Current Opinion in Chemical Biology, 2017, 40:8-16.
56	HWANG I Y, KOH E, WONG A, et al. Engineered probiotic Escherichia coli can eliminate and prevent Pseudomonas aeruginosa gut infection in animal models [J]. Nature Communications, 2017, 8(1): 15028.
57	CHOUDHARY E, THAKUR P, PAREEK M, et al. Gene silencing by CRISPR interference in mycobacteria [J]. Nature Communications, 2015, 6(1): 6267.
58	SINGH A K, CARETTE X, POTLURI L P, et al. Investigating essential gene function in Mycobacterium tuberculosis using an efficient CRISPR interference system [J]. Nucleic Acids Research, 2016, 44(18): E143.
59	YU W Y, WANG Y X, MEI J Z, et al. Overview of tuberculosis [M]. Berlin: Springer, 2020: 1-10.
60	TUMPEY T M, BASLER C F, AGUILAR P V, et al. Characterization of the reconstructed 1918 Spanish influenza pandemic virus [J]. Science, 2005, 310(5745): 77-80.
61	WEBER W, FUSSENEGGER M. Emerging biomedical applications of synthetic biology [J]. Nature Reviews Genetics, 2012, 13(1): 21-35.
62	TUMPEY T M, MAINES T R, HOEVEN N VAN, et al. A two-amino acid change in the hemagglutinin of the 1918 influenza virus abolishes transmission [J]. Science, 2007, 315(5812): 655-659.
63	SMITH G J, VIJAYKRISHNA D, BAHL J, et al. Origins and evolutionary genomics of the 2009 swine-origin H1N1 influenza A epidemic [J]. Nature, 2009, 459(7250): 1122-1125.
64	WIMMER E, MUELLER S, TUMPEY T M, et al. Synthetic viruses: a new opportunity to understand and prevent viral disease [J]. Nature Biotechnology, 2009, 27(12): 1163.
65	PERLMAN S, NETLAND J. Coronaviruses post-SARS: update on replication and pathogenesis [J]. Nature Reviews Microbiology, 2009, 7(6): 439-450.
66	BECKER M M, GRAHAM R L, DONALDSON E F, et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice [J]. PNAS, 2008, 105(50): 19944-19999.
67	BURBELO P D, CHING K H, BUSH E R, et al. Antibody-profiling technologies for studying humoral responses to infectious agents [J]. Expert Review of Vaccines, 2010, 9(6): 567-578.
68	CHANDRA A, WORMSER G P, MARQUES A R, et al. Anti-Borrelia burgdorferi antibody profile in post-Lyme disease syndrome [J]. Clinical and Vaccine Immunology, 2011, 18(5): 767-771.
69	BURBELO P D, BREN K E, CHING K H, et al. LIPS arrays for simultaneous detection of antibodies against partial and whole proteomes of HCV, HIV and EBV [J]. Molecular BioSystems, 2011, 7(5): 1453-1462.
70	DASH P K, KAMINSKI R, BELLA R, et al. Sequential LASER ART and CRISPR treatments eliminate HIV-1 in a subset of infected humanized mice [J]. Nature Communications, 2019, 10(1): 2753.
71	XU L, WANG J, LIU Y, et al. CRISPR-edited stem cells in a patient with HIV and acute lymphocytic leukemia [J]. New England Journal of Medicine, 2019, 381(13): 1240-1247.
72	LIN S R, YANG H C, KUO Y T, et al. The CRISPR/Cas9 system facilitates clearance of the intrahepatic HBV templates in vivo [J]. Molecular Therapy - Nucleic Acids, 2014, 3:E186.
73	PRICE A A, SAMPSON T R, RATNER H K, et al. Cas9-mediated targeting of viral RNA in eukaryotic cells [J]. PNAS, 2015, 112(19): 6164-6169.
74	KINDSMÜLLER K, WAGNER R. Synthetic biology: impact on the design of innovative vaccines [J]. Human Vaccines, 2011, 7(6): 658-662.
75	SUBBARAMAN N. Science snipes at Oxitec transgenic-mosquito trial [M]. London: Nature Publishing Group, 2011.
76	PEDROLLI D B, RIBEIRO N V, SQUIZATO P N, et al. Engineering microbial living therapeutics: the synthetic biology toolbox [J]. Trends in Biotechnology, 2019, 37(1): 100-115.
77	MILLER M B, BASSLER B L. Quorum sensing in bacteria [J]. Annual Reviews in Microbiology, 2001, 55(1): 165-199.
78	DUAN F, MARCH J C. Engineered bacterial communication prevents Vibrio cholerae virulence in an infant mouse model [J]. PNAS, 2010, 107(25): 11260-11264.
79	AKAHATA W, YANG Z-Y, ANDERSEN H, et al. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection [J]. Nature Medicine, 2010, 16(3): 334.
80	COLEMAN J R, PAPAMICHAIL D, SKIENA S, et al. Virus attenuation by genome-scale changes in codon pair bias [J]. Science, 2008, 320(5884): 1784-1787.
81	AMIDI M, DE RAAD M, DE GRAAUW H, et al. Optimization and quantification of protein synthesis inside liposomes [J]. Journal of Liposome Research, 2010, 20(1): 73-83.
82	DREESEN I A, CHARPIN-EL HAMRI G, FUSSENEGGER M. Heat-stable oral alga-based vaccine protects mice from Staphylococcus aureus infection [J]. Journal of Biotechnology, 2010, 145(3): 273-280.
83	SI L, XU H, ZHOU X, et al. Generation of influenza A viruses as live but replication-incompetent virus vaccines [J]. Science, 2016, 354(6316): 1170-1173.
84	LI P, KE X, WANG T, et al. Zika Virus attenuation by codon pair deoptimization induces sterilizing immunity in mouse models [J]. Journal of Virology, 2018, 92(17): E00701- E00718.
85	WANG L, WANG X, BI K, et al. Oral vaccination with attenuated salmonella typhimurium-delivered TsPmy DNA vaccine elicits protective immunity against trichinella spiralis in BALB/c Mice [J]. PLoS Negl. Trop. Dis., 2016, 10(9): E0004952.
86	STARKS H, BRUHN K W, SHEN H, et al. Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy [J]. The Journal of Immunology, 2004, 173(1): 420-427.
87	HEGAZY W A H, XU X, METELITSA L, et al. Evaluation of Salmonella enterica Type III secretion system effector proteins as carriers for heterologous vaccine antigens [J]. Infection and Immunity, 2012, 80(3): 1193-1202.
88	VALENZUELA P, MEDINA A, RUTTER W J, et al. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast [J]. Nature, 1982, 298(5872): 347-350.
89	BLANQUET S, ANTONELLI R, LAFORET L, et al. Living recombinant Saccharomyces cerevisiae secreting proteins or peptides as a new drug delivery system in the gut [J]. Journal of Biotechnology, 2004, 110(1): 37-49.
90	H-L KWAG, KIM H J, CHANG D Y, et al. The production and immunogenicity of human papillomavirus type 58 virus-like particles produced in Saccharomyces cerevisiae [J]. Journal of Microbiology, 2012, 50(5): 813-820.
91	HALLER A A, LAUER G M, KING T H, et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins [J]. Vaccine, 2007, 25(8): 1452-1463.
92	WANG X, XIAO X, ZHAO M, et al. EV71 virus-like particles produced by co-expression of capsid proteins in yeast cells elicit humoral protective response against EV71 lethal challenge [J]. BMC Research Notes, 2016, 9(1): 42.
93	RAMASAMY V, ARORA U, SHUKLA R, et al. A tetravalent virus-like particle vaccine designed to display domain III of dengue envelope proteins induces multi-serotype neutralizing antibodies in mice and macaques which confer protection against antibody dependent enhancement in AG129 mice [J]. PLoS Negl. Trop. Dis., 2018, 12(1): E0006191.
94	ATHMARAM T N, SARASWAT S, SANTHOSH S R, et al. Yeast expressed recombinant Hemagglutinin protein of novel H1N1 elicits neutralising antibodies in rabbits and mice [J]. Virology Journal, 2011, 8(1): 524.
95	HEPLER R W, KELLY R, MCNEELY T B, et al. A recombinant 63-kDa form of Bacillus anthracis protective antigen produced in the yeast Saccharomyces cerevisiae provides protection in rabbit and primate inhalational challenge models of anthrax infection [J]. Vaccine, 2006, 24(10): 1501-1514.
96	KING T H, SHANLEY C A, GUO Z, et al. GI-19007, a novel Saccharomyces cerevisiae-based therapeutic vaccine against tuberculosis [J]. Clinical and Vaccine Immunology, 2017, 24(12): E00245.
97	WALCH B, BREINIG T, GEGINAT G, et al. Yeast-based protein delivery to mammalian phagocytic cells is increased by coexpression of bacterial listeriolysin [J]. Microbes and Infection, 2011, 13(11): 908-913.
98	FU G, CONDON K C, EPTON M J, et al. Female-specific insect lethality engineered using alternative splicing [J]. Nature Biotechnology, 2007, 25(3): 353-357.
99	FU G, LEES R S, NIMMO D, et al. Female-specific flightless phenotype for mosquito control [J]. PNAS, 2010, 107(10): 4550-4554.
100	DE VALDEZ M R W, NIMMO D, BETZ J, et al. Genetic elimination of dengue vector mosquitoes [J]. PNAS, 2011, 108(12): 4772-4775.
101	RITCHIE S A, STAUNTON K M. Reflections from an old queenslander: can rear and release strategies be the next great era of vector control? [J]. Proceedings of the Royal Society B, 2019, 286(1905): 20190973.
102	WINDBICHLER N, MENICHELLI M, PAPATHANOS P A, et al. A synthetic homing endonuclease-based gene drive system in the human malaria mosquito [J]. Nature, 2011, 473(7346): 212-215.
103	WANG S, DOS-SANTOS A L A, HUANG W, et al. Driving mosquito refractoriness to Plasmodium falciparum with engineered symbiotic bacteria [J]. Science, 2017, 357(6358): 1399-1402.

[1]	Zhidian DIAO, Xixian WANG, Qing SUN, Jian XU, Bo MA. Advances and applications of single-cell Raman spectroscopy testing and sorting equipment [J]. Synthetic Biology Journal, 2023, 4(5): 1020-1035.
[2]	Hui LU, Fangli ZHANG, Lei HUANG. Establishment of iBioFoundry for synthetic biology applications [J]. Synthetic Biology Journal, 2023, 4(5): 877-891.
[3]	Zhonghu BAI, He REN, Jianqi NIE, Yang SUN. The recent progresses and applications of in-parallel fermentation technology [J]. Synthetic Biology Journal, 2023, 4(5): 904-915.
[4]	Yujie WU, Xinxin LIU, Jianhui LIU, Kaiguang Yang, Zhigang SUI, Lihua ZHANG, Yukui ZHANG. Research progress of strain screening and quantitative analysis of key molecules based on high-throughput liquid chromatography and mass spectrometry [J]. Synthetic Biology Journal, 2023, 4(5): 1000-1019.
[5]	Zhehui HU, Juan XU, Guangkai BIAN. Application of automated high-throughput technology in natural product biosynthesis [J]. Synthetic Biology Journal, 2023, 4(5): 932-946.
[6]	Huan LIU, Qiu CUI. Advances and applications of ambient ionization mass spectrometry in screening of microbial strains [J]. Synthetic Biology Journal, 2023, 4(5): 980-999.
[7]	Yannan WANG, Yuhui SUN. Base editing technology and its application in microbial synthetic biology [J]. Synthetic Biology Journal, 2023, 4(4): 720-737.
[8]	Wanqiu LIU, Xiangyang JI, Huiling XU, Yicong LU, Jian LI. Cell-free protein synthesis system enables rapid and efficient biosynthesis of restriction endonucleases [J]. Synthetic Biology Journal, 2023, 4(4): 840-851.
[9]	Meili SUN, Kaifeng WANG, Ran LU, Xiaojun JI. Rewiring and application of Yarrowia lipolytica chassis cell [J]. Synthetic Biology Journal, 2023, 4(4): 779-807.
[10]	Mengdan MA, Mengyu SHANG, Yuchen LIU. Application and prospect of CRISPR-Cas9 system in tumor biology [J]. Synthetic Biology Journal, 2023, 4(4): 703-719.
[11]	Tiantian WANG, Hong ZHU, Chen YANG. Development of CRISPRa for metabolic engineering applications in cyanobacteria [J]. Synthetic Biology Journal, 2023, 4(4): 824-839.
[12]	Jicong LIN, Gen ZOU, Hongmin LIU, Yongjun WEI. Application of CRISPR/Cas genome editing technology in the synthesis of secondary metabolites of filamentous fungi [J]. Synthetic Biology Journal, 2023, 4(4): 738-755.
[13]	Zhi SUN, Ning YANG, Chunbo LOU, Chao TANG, Xiaojing YANG. Rational design for functional topology and its applications in synthetic biology [J]. Synthetic Biology Journal, 2023, 4(3): 444-463.
[14]	Qilong LAI, Shuai YAO, Yuguo ZHA, Hong BAI, Kang NING. Microbiome-based biosynthetic gene cluster data mining techniques and application potentials [J]. Synthetic Biology Journal, 2023, 4(3): 611-627.
[15]	Qiaozhen MENG, Fei GUO. Applications of foldability in intelligent enzyme engineering and design: take AlphaFold2 for example [J]. Synthetic Biology Journal, 2023, 4(3): 571-589.